Study aims to advance treatment options for severe peripheral arterial disease

NICE recommends non‑hormonal therapy for moderate to severe vasomotor symptoms

BE BOLD trial shows bimekizumab outperforms risankizumab at Week 16

Early data show favourable safety and sustained target engagement for oral EP4 receptor antagonist

Study will assess whether microbiome therapy can protect gut diversity during transplantation

Phase 3 Mascot study reaches key milestone for potential first-in-class therapy

EC decision introduces first systemic option for adults with advanced SCAC

First‑in‑human phase 1/2a study launches in China and the US targeting advanced cancers

New funding will support the phase 2 expansion trial of THEO-260

DementAI prototype developed by Katalyze Data seeks to ease pressure on clinical teams